EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan

Chanon Nusawat, So Sato, Hideaki Watanabe, Takaaki Konishi, Hayato Yamana, Hideo Yasunaga

Clinical Drug Investigation · 2024

DOI: 10.1007/s40261-024-01399-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Chanon Nusawat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 11300…. Hauptthemen laut MEDLINE: Trastuzumab, Cost-Benefit Analysis, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labour and Welfare, The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer presents considerable treatment challenges owing to its aggressive nature. Global guidelines have endorsed a full year of HER2-targeted therapy for early-stage breast cancer. However, previous cost-effectiveness analyses of dual HER2-targeted therapies have been limited. This study aimed to examine the cost effectiveness of dual HER2-targeted therapy for early-stage breast cancer within the Japanese healthcare system context. METHODS: In the Markov model-based study, the cost effectiveness of dual anti-HER2 therapy, combining pertuzumab and trastuzumab, was assessed in comparison to trastuzumab monotherapy. Patients in whom treatment was initiated at a median age of 51 years were included. The study utilized quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) as comparison units. Subgroup analyses were conducted to explore variations in cost effectiveness, focusing on node-positive and node-negative patients. Both one-way deterministic and broader probabilistic sensitivity analyses using Monte Carlo simulations with 10,000 samples were performed from the Japanese healthcare payers perspective. RESULTS: Dual HER2-targeted therapy led to 0.17 QALYs increment at an additional cost of $US15,289, resulting in an ICER of $US92,232 per QALY. In the subgroup of node-positive patients, the benefit of the dual HER2-targeted therapy was more pronounced, with an increase of 0.64 QALYs and an ICER of $US24,561 per QALY. Sensitivity analyses revealed the model's susceptibility to changes in the transition probabilities from invasive disease-free survival to death, from invasive disease-free survival to first-line metastatic breast cancer, and to costs associated with pertuzumab. Probabilistic sensitivity analysis suggests that for node-positive patients, dual HER2-targeted therapy may be a cost-effective option. CONCLUSIONS: The economic viability of dual HER2-targeted therapy was most pronounced in patients with node-positive high-risk early breast cancer. This study highlights the potential of dual HER2-targeted therapy as a cost-effective addition for these cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabCost-Benefit AnalysisErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsAntibodies, Monoclonal, HumanizedQuality-Adjusted Life YearsMarkov ChainsHumansFemaleJapanMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantAdultAntineoplastic Agents, ImmunologicalMonte Carlo MethodAgedCost-Effectiveness Analysis

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpertuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1130033, Japan. chanon-n@g.ecc.u-tokyo.ac.jp.
  • Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1130033, Japan.
  • Department of Eat-loss Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Breast and Endocrine Surgery, The University of Tokyo, Tokyo, Japan.
  • Data Science Center, Jichi Medical University, Tochigi, Japan.

Förderung

  • Ministry of Health, Labour and Welfare
  • The University of Tokyo

Zitieren

APA

Nusawat, C., Sato, S., Watanabe, H., Konishi, T., Yamana, H., & Yasunaga, H. (2024). Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01399-3

Vancouver

Nusawat C, Sato S, Watanabe H, Konishi T, Yamana H, Yasunaga H. Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01399-3

BibTeX
@article{Nusawat2024,
  author = {Nusawat, Chanon and Sato, So and Watanabe, Hideaki and Konishi, Takaaki and Yamana, Hayato and Yasunaga, Hideo},
  title = {Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan},
  journal = {Clinical Drug Investigation},
  year = {2024},
  doi = {10.1007/s40261-024-01399-3}
}
Kostenlos starten →